Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
MARCO Biologics Sequence Review Report 2026: Macrophage receptor MARCO Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MARCO sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEE1 Biologics Sequence Review Report 2026: Melanoma-associated antigen E1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEE1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGED4 Biologics Sequence Review Report 2026: Melanoma-associated antigen D4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGED4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGED2 Biologics Sequence Review Report 2026: Melanoma-associated antigen D2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGED2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGED1 Biologics Sequence Review Report 2026: Melanoma-associated antigen D1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGED1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEC3 Biologics Sequence Review Report 2026: Melanoma-associated antigen C3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEC3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEC2 Biologics Sequence Review Report 2026: Melanoma-associated antigen C2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEC2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB6 Biologics Sequence Review Report 2026: Melanoma-associated antigen B6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB4 Biologics Sequence Review Report 2026: Melanoma-associated antigen B4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB2 Biologics Sequence Review Report 2026: Melanoma-associated antigen B2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB18 Biologics Sequence Review Report 2026: Melanoma-associated antigen B18 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB18 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA8 Biologics Sequence Review Report 2026: Melanoma-associated antigen 8 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
879
880
881
882
883
>>
2926
>